Moxifloxacin should be avoided in patients who have experienced any of the serious adverse reactions associated with fluoroquinolones.
Moxifloxacin should be avoided in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.
Moxifloxacin should be avoided in patients who have experienced peripheral neuropathy.
Moxifloxacin should be used in patients with known or suspected CNS disorders (e.g., severe cerebral arteriosclerosis, epilepsy) or other risk factors that predispose to seizures or lower seizure threshold only if potential benefits of the drugs outweigh risks.
Moxifloxacin should be avoided in patients with a known history of myasthenia gravis. Patients should be advised to immediately contact a clinician if they have any symptom of muscle weakness, including respiratory difficulties.
Moxifloxacin should be avoided in patients with known prolongation of the QT interval, ventricular arrhythmias (including torsades de points), any ongoing proarrhythmic conditions (including clinically important bradycardia and acute myocardial ischemia), or uncorrected hypokalemia or hypomagnesemia.
Moxifloxacin also should be avoided in patients receiving class IA (e.g., quinidine, procainamide) or III (e.g., amiodarones, sotalol) antiarrhythmic agents or other drugs that prolong the QT interval (e.g., cisapride, erythromycin, antipsychotic agents, tricyclic antidepressants).